The sales of nervous system medicines in Canada exhibit a steady increase from 2024 to 2028, with values rising from $149.7 to $159 in US Dollars PPP per capita. This growth reflects a moderate year-on-year increase, sustaining approximately 1.6% annually. The compound annual growth rate (CAGR) over this five-year period forecasts a consistent market expansion, suggesting stable demand and innovation within the sector.
Future trends to watch include:
- Technological advancements in drug delivery and personalized medicine, potentially accelerating market growth.
- Regulatory changes affecting market dynamics, especially with new therapeutic approvals.
- Shifts in healthcare policies and reimbursement strategies influencing accessibility and pricing.
